PA
ABUS icon

Profund Advisors’s Arbutus Biopharma ABUS Stock Holding History

Profund Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Sell
53,017
-3,240
-6% -$14.2K 0.01% 922
2026
Q1 		$253K Buy
56,257
+11,128
+25% +$48.7K 0.01% 870
2025
Q4 		$217K Buy
45,129
+31,401
+229% +$141K 0.01% 1113
2025
Q3 		$62.3K Sell
13,728
-6,592
-32% -$24.2K ﹤0.01% 1043
2025
Q2 		$62.8K Buy
20,320
+1,205
+6% +$4K ﹤0.01% 983
2025
Q1 		$66.7K Sell
19,115
-11,113
-37% -$37.1K ﹤0.01% 974
2024
Q4 		$98.8K Buy
30,228
+5,416
+22% +$19.9K ﹤0.01% 1071
2024
Q3 		$95.5K Buy
+24,812
New +$95.2K ﹤0.01% 1115

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Profund Advisors's ABUS Position: Q2 2026 in Review

Profund Advisors reduced its Arbutus Biopharma (ABUS) stake by 5.8% in Q2 2026, selling an estimated $14.2K and leaving 53,017 shares worth $254K. The position accounts for 0.01% of the portfolio, ranked #922.

Profund Advisors first reported a position in ABUS in Q3 2024 and has held it in 8 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Profund Advisors held 53,017 shares of Arbutus Biopharma worth $254K as of Q2 2026.
  • Profund Advisors sold 3,240 Arbutus Biopharma shares in Q2 2026, an estimated $14.2K.
  • Arbutus Biopharma made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #922 holding.
  • Profund Advisors first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 8 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.